Application of Physiologically Based Pharmacokinetic Modeling in Predicting Drug-drug Interactions for Sarpogrelate Hydrochloride in Humans

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2016 Oct 4

PMID 27695293

Authors

Jee Sun Min

Doyun Kim

Jung Bae Park

Hyunjin Heo

Soo Hyeon Bae

Jae Hong Seo

Euichaul Oh

Soo Kyung Bae

Affiliations

Soon will be listed here.

Abstract

Background: Evaluating the potential risk of metabolic drug-drug interactions (DDIs) is clinically important.

Objective: To develop a physiologically based pharmacokinetic (PBPK) model for sarpogrelate hydrochloride and its active metabolite, ()-1-{2-[2-(3-methoxyphenyl)ethyl]-phenoxy}-3-(dimethylamino)-2-propanol (M-1), in order to predict DDIs between sarpogrelate and the clinically relevant cytochrome P450 (CYP) 2D6 substrates, metoprolol, desipramine, dextromethorphan, imipramine, and tolterodine.

Methods: The PBPK model was developed, incorporating the physicochemical and pharmacokinetic properties of sarpogrelate hydrochloride, and M-1 based on the findings from in vitro and in vivo studies. Subsequently, the model was verified by comparing the predicted concentration-time profiles and pharmacokinetic parameters of sarpogrelate and M-1 to the observed clinical data. Finally, the verified model was used to simulate clinical DDIs between sarpogrelate hydrochloride and sensitive CYP2D6 substrates. The predictive performance of the model was assessed by comparing predicted results to observed data after coadministering sarpogrelate hydrochloride and metoprolol.

Results: The developed PBPK model accurately predicted sarpogrelate and M-1 plasma concentration profiles after single or multiple doses of sarpogrelate hydrochloride. The simulated ratios of area under the curve and maximum plasma concentration of metoprolol in the presence of sarpogrelate hydrochloride to baseline were in good agreement with the observed ratios. The predicted fold-increases in the area under the curve ratios of metoprolol, desipramine, imipramine, dextromethorphan, and tolterodine following single and multiple sarpogrelate hydrochloride oral doses were within the range of ≥1.25, but <2-fold, indicating that sarpogrelate hydrochloride is a weak inhibitor of CYP2D6 in vivo. Collectively, the predicted low DDIs suggest that sarpogrelate hydrochloride has limited potential for causing significant DDIs associated with CYP2D6 inhibition.

Conclusion: This study demonstrated the feasibility of applying the PBPK approach to predicting the DDI potential between sarpogrelate hydrochloride and drugs metabolized by CYP2D6. Therefore, it would be beneficial in designing and optimizing clinical DDI studies using sarpogrelate as an in vivo CYP2D6 inhibitor.

References

Noh Y, Lee J, Shin S, Lim H, Bae S, Oh E . Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. PLoS One. 2016; 11(3):e0150475. PMC: 4777511. DOI: 10.1371/journal.pone.0150475. View

Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S . Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke. 2008; 39(6):1827-33. DOI: 10.1161/STROKEAHA.107.505131. View

Leong R, Vieira M, Zhao P, Mulugeta Y, Lee C, Huang S . Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012; 91(5):926-31. DOI: 10.1038/clpt.2012.19. View

Yamashita S, Tachiki H . Analysis of risk factors in human bioequivalence study that incur bioinequivalence of oral drug products. Mol Pharm. 2008; 6(1):48-59. DOI: 10.1021/mp800140m. View

Yang J, Kim J, Cho E, Huh W, Ko J, Lee S . A Novel Simultaneous Determination of Sarpogrelate and its Active Metabolite (M-1) in Human Plasma, Using Liquid Chromatography-Tandem Mass Spectrometry: Clinical Application. Ann Lab Med. 2015; 35(4):391-8. PMC: 4446576. DOI: 10.3343/alm.2015.35.4.391. View

Sinha V, Zhao P, Huang S, Zineh I . Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy. Clin Pharmacol Ther. 2014; 95(5):478-80. DOI: 10.1038/clpt.2014.46. View

Mao Q, Unadkat J . Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J. 2014; 17(1):65-82. PMC: 4287283. DOI: 10.1208/s12248-014-9668-6. View

OBrien F, Dinan T, Griffin B, Cryan J . Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol. 2011; 165(2):289-312. PMC: 3268186. DOI: 10.1111/j.1476-5381.2011.01557.x. View

Kim H, Jeong E, Seo K, Shin K, Choi Y, Lee S . Glucuronidation of a sarpogrelate active metabolite is mediated by UDP-glucuronosyltransferases 1A4, 1A9, and 2B4. Drug Metab Dispos. 2013; 41(8):1529-37. DOI: 10.1124/dmd.113.051862. View

10.

Kim T, Kim J, Jung J, Kim S, Lee J, Jun H . Comparison of pharmacokinetics between sarpogrelate hydrochloride immediate-release formulation and controlled-release formulation. Int J Clin Pharmacol Ther. 2012; 51(2):114-9. DOI: 10.5414/CP201777. View

11.

Miyazaki M, Higashi Y, Goto C, Chayama K, Yoshizumi M, Sanada H . Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol. 2007; 49(4):221-7. DOI: 10.1097/FJC.0b013e3180325af3. View

12.

Satoh T, Taylor P, Bosron W, Sanghani S, Hosokawa M, La Du B . Current progress on esterases: from molecular structure to function. Drug Metab Dispos. 2002; 30(5):488-93. DOI: 10.1124/dmd.30.5.488. View

13.

Kim T, Kim J, Jung J, Kim M, Lee S, Ko J . Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food. J Clin Pharm Ther. 2013; 39(2):192-5. DOI: 10.1111/jcpt.12117. View

14.

Damy T, Pousset F, Caplain H, Hulot J, Lechat P . Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004; 18(1):113-23. DOI: 10.1046/j.1472-8206.2003.00216.x. View

15.

Balimane P, Marino A, Chong S . P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?. AAPS J. 2008; 10(4):577-86. PMC: 2628205. DOI: 10.1208/s12248-008-9068-x. View

16.

Erceg M, Cindric M, Pozaic Frketic L, Vertzoni M, Cetina-cizmek B, Reppas C . A LC-MS-MS method for determination of low doxazosin concentrations in plasma after oral administration to dogs. J Chromatogr Sci. 2010; 48(2):114-9. DOI: 10.1093/chromsci/48.2.114. View

17.

Evans M, Crank W, Yang H, Simmons J . Applications of sensitivity analysis to a physiologically based pharmacokinetic model for carbon tetrachloride in rats. Toxicol Appl Pharmacol. 1994; 128(1):36-44. DOI: 10.1006/taap.1994.1177. View

18.

Zhang C, Wang L, Yang Y, Sun Y, Zhang J, Li G . Validated LC-MS/MS method for the determination of sarpogrelate in human plasma: application to a pharmacokinetic and bioequivalence study in Chinese volunteers. J Pharm Biomed Anal. 2010; 53(3):546-51. DOI: 10.1016/j.jpba.2010.03.025. View

19.

Huang S . PBPK as a tool in regulatory review. Biopharm Drug Dispos. 2012; 33(2):51-2. DOI: 10.1002/bdd.1777. View

20.

VandenBrink B, Foti R, Rock D, Wienkers L, Wahlstrom J . Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos. 2011; 40(1):47-53. DOI: 10.1124/dmd.111.041210. View